VistaStem Therapeutics is the wholly owned subsidiary of VistaGen Therapeutics, Inc. focused on applying our human pluripotent stem cell (hPSC) technology platform and CardioSafe 3Dâ„¢, our customized in-vitro cardiac cell bioassay system, to predict potential heart toxicity of new chemical entities (NCEs) long before they are tested in preclinical animal studies and human clinical studies. Having successfully assessed AV-101 and numerous other drug candidates to establish the clinically predictive capabilities of CardioSafe 3D, we are utilizing CardioSafe 3D to expand our pipeline through cardiac liability-focused small molecule drug rescue, and to participate, together with a select group of pharmaceutical and biotechnology companies, in the FDA's Comprehensive in-vitro Proarrhythmia Assay (CIPA) initiative designed to change the landscape of preclinical drug development by providing a more complete and accurate assessment of potential drug effects on cardiac risk.

We are also leveraging our stem cell technology to discover, rescue, develop and commercialize small molecule NCEs for central nervous system (CNS) and other diseases including NCEs with regenerative potential, as well as innovative regenerative medicines and cellular therapies across a range of cell types, including blood, bone, cartilage, heart and liver cells. We have entered into an exclusive sublicense agreement with BlueRock Therapeutics L.P, a next generation regenerative medicine company established by Bayer AG and Versant Ventures, for our rights to proprietary technologies relating to the production of cardiac stem cells for the treatment of heart disease.